HCA
PCVX icon

Harbor Capital Advisors’s Vaxcyte PCVX Stock Holding History

Harbor Capital Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,274
Closed -$1.44M – 1425
2025
Q4 		$1.44M Buy
31,274
+252
+0.8% +$11.3K 0.11% 249
2025
Q3 		$1.12M Sell
31,022
-71,340
-70% -$2.36M 0.09% 295
2025
Q2 		$3.33M Buy
102,362
+25,303
+33% +$829K 0.14% 214
2025
Q1 		$2.91M Buy
77,059
+2,152
+3% +$172K 0.13% 225
2024
Q4 		$6.13M Buy
74,907
+10,243
+16% +$1.02M 0.27% 116
2024
Q3 		$7.39M Buy
64,664
+24,322
+60% +$2.19M 0.32% 90
2024
Q2 		$3.05M Buy
40,342
+32,149
+392% +$2.19M 0.23% 125
2024
Q1 		$560K Buy
+8,193
New +$567K 0.07% 360

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harbor Capital Advisors's PCVX Position: Q1 2026 in Review

Harbor Capital Advisors sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 31,274 shares — an estimated $1.44M sold.

Harbor Capital Advisors first reported a position in PCVX in Q1 2024 and held it in 8 quarters. The position peaked at $7.39M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Harbor Capital Advisors reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
  • Harbor Capital Advisors sold 31,274 Vaxcyte shares in Q1 2026, an estimated $1.44M.
  • Harbor Capital Advisors first reported a position in Vaxcyte in Q1 2024 and held it in 8 quarters.
  • Harbor Capital Advisors's Vaxcyte position peaked at $7.39M in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.